Details checkedClinical trial listing onlyHistorical/discontinuedCheckedpublication

Selurampanel (BGG492) by Novartis

Also known as: BGG492, BGG492A, BGG-492, BGG-492A, Selurampanel, CBGG492A2210, NCT01302873, 2010-022166-27

Novartis Pharmaceuticals

Primary source

Company

Novartis Pharmaceuticals

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Oral treatment

Confidence

86%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Germany, Netherlands

Population

adult, tinnitus

Trial IDs

Mechanism

Oral small-molecule AMPA/kainate receptor antagonist evaluated as BGG492/selurampanel for chronic subjective tinnitus.

Indications

Tinnitus

Notes

Verified as a real Novartis-sponsored Phase 2 proof-of-concept study of BGG492/selurampanel in chronic subjective tinnitus. The ClinicalTrials.gov/ICH GCP registry record identifies the sponsor, trial design, AMPA-receptor-antagonist keyword, and linked 2021 publication of single- and repeated-dose selurampanel results. No current active Novartis tinnitus development signal was confirmed in this pass, so this should be treated as a historical completed program rather than an active pipeline asset.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, programType, modality, mechanism, indications...

IDs: NCT01302873, CBGG492A2210, 2010-022166-27

Open

registry mirror

Supports: canonicalName, aliases, company, modality, mechanism, indications, stage, status...

IDs: NCT01302873, BGG492A, selurampanel

Open

publication

Supports: canonicalName, aliases, mechanism, stage, status, notes